A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer

Abstract

Supplemental Digital Content is available in the text.

Automatic data extraction to support meta-analysis statistical analysis: a case study on breast cancer

“…To evaluate the performance of the proposed system, we selected a published meta-analysis and used our system to reproduce the results. The selected meta-analysis was conducted by Feng et al [ 19 ] and examines the effect of platinum-based neoadjuvant chemotherapy on resectable triple-negative breast cancer patients. The meta-analysis consists of nine studies, Alba et al [ 20 ], Ando et al [ 21 ], Gluz et al [ 22 ], Loibl et al [ 23 ], Sikov et al [ 24 ], Tung et al [ 25 ], Minckwitz et al [ 26 ], Wu et al [ 27 ], and Zhang et al [ 28 ].…”

Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis

“…Prior meta-analyses [ 10 , 11 ] have demonstrated higher pCR rates with the addition of platins in the neoadjuvant setting, but whether this improves survival outcomes is unclear [ 12 , 13 ]. We designed this systematic review to analyse if carboplatin in addition to neoadjuvant or adjuvant therapy in TNBC leads to better DFS and OS in patients compared to standard AT chemotherapy.…”

Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer

“…1 H NMR (300 MHz, Chloroform-d) δ 6.15 (s, 6H), 5.54 (s, 1H), 4.80 (d, J = 2.5 Hz, 2H), 3.75 (s, 2H), 3.67 (t, J = 3.9 Hz, 2H), 3.54 (s, 2H), 3.49 (s, 2H), 3.04 (s, 2H), 2.68 (s, 2H), 2.60 (t, J = 2.3 Hz, 2H), 2.17 (s, 1H), 1.50−1.35 (m, 2H), 1.30−1.21 (m, 30H), and 0.86 (t, J = 6.4 Hz, 3H). 13 Synthesis of (11). Compound 8 (100 mg, 0.262 mmol) was placed into a 10 mL glass vial and dissolved with anhydrous DMSO solution (3 mL).…”

“…Pt derivatives, including cisplatin (DDP) and carboplatin, have gained renewed attention for the treatment of TNBC. Clinical data has demonstrated the effectiveness of Pt drugs in TNBC and breast cancer gene 1 (BRCA1)-associated breast cancer. , Combination therapy involving Pt drugs with other chemotherapeutic drugs has emerged as an ideal approach for chemotherapy in patients with BC …”

“…9,10 Combination therapy involving Pt drugs with other chemotherapeutic drugs has emerged as an ideal approach for chemotherapy in patients with BC. 11 Currently, the clinically approved Pt drugs are all square planar Pt(II) drugs, which possess two inert ammonia bases and labile chlorido-or O-containing ligands in cis-positions, such as DDP, carboplatin, and oxaliplatin. Despite their wide clinical use, Pt(II) drugs have some disadvantages, such as tissue toxicity, low therapeutic index, etc.…”